COMMUNIQUÉS West-GlobeNewswire

Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
13/04/2026
Portage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a [...]
BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference
13/04/2026
BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
13/04/2026
VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
CVRx Reports Preliminary First Quarter 2026 Financial Results
13/04/2026
Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 Early data in 2026 shows an increase in the 30- [...]
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
13/04/2026
Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug [...]
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
13/04/2026
AKB-9090 is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a [...]
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
13/04/2026
Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis to present 3 oral [...]
Catheter Precision Announces Accepted Publication in Leading European Medical Journal
13/04/2026
Clinical Evidence Further Demonstrates Efficacy and Accuracy of VIVO for Ventricular Procedures FORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company [...]
ImPact Biotech Presents Preliminary Data from Phase 1 Study of Padeliporfin VTP in LA-PDAC at SIR 2026 and Provides Strategic Business Update
13/04/2026
– Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile – – LA-PDAC program represents large market opportunity [...]
Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa
13/04/2026
Managed Access Program to support physician-led access to nine rare-disease therapies in accordance with local regulatory frameworks ZUG, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- Veld Pharmaceuticals GmbH (“Veld [...]
With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository
13/04/2026
- Firefly’s total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters - - Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to power next-generation [...]
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
13/04/2026
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative [...]
Glass House Brands Announces California Retail Joint Venture with Vireo Growth
13/04/2026
LONG BEACH, Calif. and TORONTO, April 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) and Vireo Growth Inc. ("Vireo") (CSE: [...]
Vireo Growth Announces California Retail Joint Venture with Glass House Brands
13/04/2026
MINNEAPOLIS and LONG BEACH, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Glass House Brands Inc. (“Glass House”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: [...]
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
13/04/2026
Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership Author of a visionary 2015 Journal of Investigative [...]
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
13/04/2026
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active [...]
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
13/04/2026
41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30% MRD Reduction Occurred Rapidly Following Cema-Cel Treatment with a 97.7% [...]
Gelatide Drops Investigated (2026 Report) What Consumers Should Verify Before Buying
13/04/2026
A 2026 consumer-focused evaluation of Gelatide that analyses its marketing claims, ingredient profile, pricing structure, and key factors consumers should verify before making a purchase. Los Angeles, April 13, 2026 ( [...]
From Milestone to Momentum: Kraig Biocraft Leadership Travels to South East Asia Following Record-Setting 1.3 Metric Ton Recombinant Spider Silk Cocoon Production Cycle
13/04/2026
ANN ARBOR, Mich., April 13, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that senior [...]

Pages